Clinical Trial Update: Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating limertinib in combination with carboplatin and etoposide for EGFR-mutant non-small cell lung cancer with transformation to sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• Limertinib (Limertinib)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Small Cell Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING